Role of dexamethasone on vasopressin release during endotoxemic shock

Regulatory Peptides

Volumn 147, Issue 1-3, 2008, Pages 67-71

  Batalhao M E ^a   Moreto, V ^a   Stabile, A M ^a   Antunes Rodrigues, J ^a   Carnio, E C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blood pressure; Endotoxemia; Endotoxin; Glucocorticoids; Lipopolisaccharide; Nitric oxide

Indexed keywords

DEXAMETHASONE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; SODIUM CHLORIDE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; HEART RATE; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SEPTIC SHOCK;

ANIMALS; BLOOD PRESSURE; DEXAMETHASONE; GLUCOCORTICOIDS; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; SHOCK, SEPTIC; VASOPRESSINS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 40849083453     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.01.001     Document Type: Article

References (34)

1. Angus D., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1472-1474
2. Brun-Buisson C., Doyon F., Carlet J., Dellarmonica P., Gouin F., Lepoutre A., Mercier J.C., Offestadt G., and Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. J Am Med Assoc 274 (1995) 968-974
3. Parrillo J.E., Parker M.M., Natanson C., Suffredini A.F., Danner R.L., Cunnion R.E., and Ognibene F.P. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113 (1990) 227-242
4. Groeneveld A.B., Bronsveld W., and Thijs L.G. Haemodynamic determinants of mortality in human septic shock. Surgery 99 (1986) 140-153
5. Baumgartner J.D., and Calandra T. Treatment of sepsis: past and future avenues. Drugs 7 (1995) 127-132
6. Giusti-Paiva A., De Castro M., Antunes-Rodrigues J., and Cárnio E.C. Inducible nitric oxide synthase in the central nervous system and vasopressin release during experimental septic shock. Crit Care Med 30 (2002) 1306-1309
7. Vincent J.L., Zhang H., and Szabo C. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 161 (2000) 1781-1785
8. Thiemermann C., and Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 182 (1990) 591-595
9. Aranow J., Zhuang J., Wang H., Larkin V., Smith M., and Fink M.O. A selective inhibitor of inducible nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis. Comparison with two nonselective strategies. Shock 5 (1996) 116-121
10. Szabo C., Southan G.J., and Thiemermann C. Benefficial effects and improved survival in rodent models of septic shock with S-methylsothiourea sulphate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci 91 (1994) 12472-12476
11. Bone R.C., Fisherm C.J., Clemmer T.P., Slotman G.H., Metz C.A., and Balk R.A. The methylprednisolone Severe Sepsis Study Group. A controlled clinical trial of high doses methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317 (1987) 653-658
12. Bellissant E., and Ananne D. Effect of hydrocortisone on phenylphine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 68 (2000) 293-303
13. Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audibert G., and Larca A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26 (1998) 645-650
14. Briegel J., Forst H., Haller M., Sheling G., Kilger E., Kuprat G., Hemmer B., Hummel T., Lenhart A., Heyduck M., Stoll C., and Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind single-center study. Crit Care Medic 27 (1999) 723-732
15. Ota M., Crofton J.T., and Festavan G.T. Evidence that nitric oxide can act centrally to stimulate vasopressin release. Neuroendocrinology 57 (1993) 955-959
16. Yasin S., Costa A., and Trainer P. Nitric oxide modulates the release of vasopressin from rat hypothalamic explants. Endocrinology 133 (1993) 1466-1469
17. Kadekaro M., Terrell M.L., and Liu H. Effects of l-NAME on cerebral metabolic, vasopressin, oxytocin, and blood pressure in haemorrhage rats. Am J Physiol 274 (1998) R1070-R1077
18. Stern J.E., and Ludwig M. NO inhibits supraoptic oxytocin and vasopressin neurons via activation of GABAergic synaptic inputs. Am J Physiol, Regul Integr Comp Physiol 280 (2001) R1815-R1822
19. Radomski M.W., Palmer M.R.J., and Moncada S. Glucocorticoids inhibit the expression of an inducible but not constitutive nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci 87 (1990) 10043-10047
20. Archer S. Measurement of nitric oxide in biological models. FASEB J 7 (1993) 349-360
21. Cronin L., Cook D.J., Carlet J., Heyland D.K., King D., Lansang M.A., and Fisher C.J. Corticosteroid treatment for sepsis: a critical appraisal and metanalysis of the literature. Crit Care Med 23 (1995) 1430-1439
22. Annane D., Sebille V., Charpentier C., Bollaertt E., François B., Korach J.M., Capellier G., Cohen Y., Azoulay E., Troche G., Chaumet-Riffaut P., and Bellissant E. Effect of treatment with low doses of hydrocortisone and fluocortisone on mortality in patients with septic shock. J Am Med Assoc 288 (2002) 862-871
23. Sprung C.L., Caralis P.V., Marcial E.H., Pierce M., Gelbard M.A., Long W.M., Duncan R.C., Tendler M.D., and Karpf M. The effects of high dose corticosteroids in patients with septic shock. A prospective controlled study. N Engl J Med 311 (1984) 1137-1143
24. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and the immune-mediated inflammation. N Eng J Medic 332 (1995) 1351-1362
25. Simmons W.W., Ungureanu-Longrois D., Smith D., Smith A., and Kelly R.A. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and l-arginine transport. J Biol Chem 271 (1996) 23928-23937
26. Keh D., Boehnke T., Weber-Cartens S., Schulz C., Ahlers O., Bercker S., Volk H.D., Doecke W.D., Falke K.J., and Gerlach H. Immunological and hemodynamic effects of "low dose" of hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167 (2003) 512-520
27. Rosselet A., Feihl F., Markert M., Gnaegi A., Perret G., and Liaudet L. Selective iNOS inhibitor is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 157 (1998) 162-170
28. Altavilla D., Squadrito F., Campo G.M., Squadrito G., Arlotta M., Urna G., Sardella A., Quatorone C., Saitta A., and Caputi A.P. The lazaroid, U-74389G, inhibits indicible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur J Pharmacol 369 (1999) 49-55
29. G-methyl-l-arginine hydrochloride (546C88), in patients with septic shock. Crit Care Med 27 (1999) 913-922
30. Lopez A., Lorente J.A., and Steingrub J. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32 (2004) 21-30
31. Charmandari E., Tsigos C., and Chrousos G. Endocrinology of the stress response. Ann Rev Physiol 67 (2005) 259-284
32. Tsuneyoshi I., Yamada H., and Kakihana Y. Hemodynamic and metabolic effects of low-dose vasopressin infusion in vasodilatory septic shock. Crit Care Med 29 (2001) 487-493
33. Holmes C.L., Patel B., and Russell J.A. Physiology of vasopressin relevant to management of septic shock. Chest 120 (2001) 989-1002
34. Landry D.W., Levin H.R., and Gallant E.M. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 25 (1997) 1279-1282